Literature DB >> 12850901

Association of benzodiazepine injection with the prescription of temazepam capsules.

Malcolm Dobbin1, Raymond F Martyres, Danielle Clode, Fleur E Champion De Crespigny.   

Abstract

Temazepam capsules have become a popular choice for benzodiazepine injection by injecting drug users, and serious vascular and tissue damage leading to ulcers and gangrene can result. We compared the self-reported benzodiazepine injecting behaviour of 91 heroin users with their Pharmaceutical Benefits Schedule (PBS) records for the preceding 5 years. We found that individuals prescribed PBS temazepam capsules were more likely to report injecting benzodiazepines than individuals who had either not been prescribed PBS temazepam capsules or had been prescribed PBS temazepam tablets. These results provide empirical support for the argument to limit the prescription and supply of temazepam capsules in Australia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12850901     DOI: 10.1080/09595230100100589

Source DB:  PubMed          Journal:  Drug Alcohol Rev        ISSN: 0959-5236


  3 in total

1.  Assessment of a formulation designed to be crush-resistant in prescription opioid abusers.

Authors:  Suzanne K Vosburg; Jermaine D Jones; Jeanne M Manubay; Judy B Ashworth; Irma H Benedek; Sandra D Comer
Journal:  Drug Alcohol Depend       Date:  2012-06-20       Impact factor: 4.492

2.  The epidemiology of benzodiazepine misuse: A systematic review.

Authors:  Victoria R Votaw; Rachel Geyer; Maya M Rieselbach; R Kathryn McHugh
Journal:  Drug Alcohol Depend       Date:  2019-05-07       Impact factor: 4.492

3.  Protocol: changes in rates of opioid overdose and poisoning events in an integrated health system following the introduction of a formulation of OxyContin® with abuse-deterrent properties.

Authors:  Shannon L Janoff; Nancy A Perrin; Paul M Coplan; Howard D Chilcoat; Cynthia I Campbell; Carla A Green
Journal:  BMC Pharmacol Toxicol       Date:  2016-05-14       Impact factor: 2.483

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.